CAR T cells targeting CD19 and CD20 for relapsed B-cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new type of CAR T-cell therapy that targets two markers (CD19 and CD20) on B-cell cancer cells. It is for people whose B-cell leukemia or lymphoma has come back or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a B-cell blood cancer that is CD19 or CD20 positive (confirmed by a lab test).
- Your cancer has either come back after treatment or hasn't responded to standard therapy.
- You must have measurable disease (for lymphoma, at least one lymph node >1.5 cm; for leukemia, a positive minimal residual disease test).
- You should be in fairly good health (ECOG performance status 0-2, meaning you can do daily activities with little or no help).
- You cannot have serious heart problems, active infections, or other advanced cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy that uses your own immune cells engineered to recognize two cancer targets (CD19 and CD22) to treat B-cell blood cancers that have come back or not responded to standard treatments. It may offer a treatment option when other therapies have stopped working.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on cancer cells. It is for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to other treatments.
This trial tests a new type of immunotherapy called bispecific CAR T cells that target two markers (CD19 and CD20) on cancer cells. It is for people with certain B-cell blood cancers that have come back or not responded to other treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
This trial tests a locally made CAR T-cell therapy that targets CD19 on cancer cells. It is for children and young adults with certain B-cell cancers that have come back or not responded to other treatments.
Hear when a new B-Cell Lymphoblastic Leukemia/Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.